

## ***Prof.Dr. Umut Kalyoncu'nun Özgeçmişi***

Prof. Dr. Umut Kalyoncu Ocak 1976'da İzmir'in Bergama ilçesinde doğmuştur. Evli ve iki çocuk sahibidir. Umut Kalyoncu ilkokul ve ortaokulu Bergama'da okuduktan sonra Lise 1 ve 2 eğitimini Trabzon Yomra Fen Lisesinde tamamlamıştır. Bergama Lisesinden mezun olmuştur. 1992 yılında Hacettepe Üniversitesi Tıp Fakültesi Türkçe bölümünde eğitimine tıp başlamıştır. Bir yılı İngilizce hazırlığı olmak üzere 7 yıllık tıp fakültesi eğitimini 1999 yılında bitirerek mezun olmuştur. 2000 yılında Hacettepe üniversitesi Tıp fakültesi iç hastalıkları anabilim dalında asistanlık eğitimine başlamıştır. 2003-2004 yılları arasında başasistan olarak çalışmıştır. 2004 yılında Hacettepe üniversitesinde Romatoloji yan dalına başlamıştır. 2007 yılında romatoloji yan dal uzmanlığını almıştır. 2007-2010 yılları arasında Romatoloji bilim dalında uzman olarak çalışmıştır. 2010-2011 yılları arasında GATA'da askerliğini tamamlamıştır. 2011 yılında doçentlik unvanını almıştır. 2011-2012 yılları arasında Antakya devlet hastanesinde devlet hizmet yükümlülüğünü yerine getirmiştir. 2013 yılında Hacettepe üniversitesi iç hastalıkları anabilim dalı, romatoloji bilim dalında öğretim üyesi olarak çalışmaya başlamıştır ve halen aynı bölümde çalışmalarına devam etmektedir.

Prof.Dr. Umut Kalyoncu 2007 yılında 4 ay süresince Fransa'da Paris Cochin hastanesinde romatoloji ve epidemiyoloji konularında gözlemci olarak bulunmuştur. 2015-2016 yılları arasında bir yıl süreyle Birleşik Devletlerin Maryland eyaletinde Johns Hopkins Üniversitesinde klinik Romatoloji bölümünde araştırmacı fellow olarak çalışmış ve post-doc'ünü tamamlamıştır. Temel araştırma konusu psöriatik arttır. 2011 yılından itibaren uluslararası psöriatik artrit cemiyeti olan GRAPPA'nın üyesidir. Hakemli dergilerde yayınlanmış 82 orijinal çalışması vardır. Web of Science veri tabanına göre 224 bilimsel çalışması bulunmaktadır. Bu çalışmalara Aralık 2017 itibarıyla 1046 atıf yapılmıştır, h-skoru 15'dir. Türk İç Hastalıkları Derneği ve Türkiye Romatoloji Derneği üyesidir.

İlgilendiği romatizmal hastalıklar şunlardır; Spondiloartritler (Ankilozan spondilit, psöriatik artrit, enteropatik artrit), romatoid artrit, bağ dokusu hastalıkları (Sistemik lupus eritematosus, sjögren sendromu, skleroderma, polimyozit, dermatomyozit), ailesel akdeniz ateşi (FMF), Behçet hastalığı, Sarkoidoz ve vaskülitler (lökositoklastik vaskülitler, henoch schönlein purpurası, poliarteritis nodoza, takayasu arteriti, dev hücreli arterit, wegener granülomatosis, churgh-strauss sendromu ve mikroskobik polianjitis).

## Prof.Dr. Umut Kalyoncu'nun konularına göre akademik çalışmaları

### Psöriatik Artrit

1. **Kalyoncu U**, Gossec L, Nguyen M, Berdah L, Mazières B, Lequesne M, Dougados M. Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: results of a 10 years follow-up study of 507 patients (ECHODIAH study). *Joint Bone Spine*. 2009;76:389-93.
2. Gossec L, de Wit M, Kiltz U, Braun J, **Kalyoncu U**, Scivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis*. 2014;73:1012-9.
3. Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, **Kalyoncu U**, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. *Joint Bone Spine*. 2016;83:335-40.
4. **Kalyoncu U**, Ogdie A, Campbell W, Bingham CO 3rd, de Wit M, Gladman DD, Mease P, Steinkoenig I, Strand V, Riese VG, Orbai AM. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. *RMD Open*. 2016 Mar 3;2(1):e000217. doi:10.1136/rmdopen-2015-000217.
5. Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A, Balint PV, Niedermayer DS, Cañete JD, Helliwell P, **Kalyoncu U**, Kiltz U, Otsa K, Veale DJ, de Vlam K, Scivo R, Stamm T, Kvien TK, Gossec L. Fatigue in psoriatic arthritis – across-sectional study of 246 patients from 13 countries. *Joint Bone Spine*. 2016;83:439-43.
6. Orbai AM, Mease PJ, de Wit M, **Kalyoncu U**, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A. Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. *J Rheumatol*. 2016;43:965-9.
7. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, **Kalyoncu U**, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis*. 2017;76:673-680.
8. **Kalyoncu U**, Bayindir Ö, Ferhat Öksüz M, Doğru A, Kimyon G, Tarhan EF, Erden A, Yavuz Ş, Can M, Çetin GY, Kılıç L, Küçükşahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yilmazer B, Atakan N, Aydın SZ; Psoriatic Arthritis Registry of Turkey Study Group. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. *Rheumatology (Oxford)*. 2017;56:279-286.

9. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, **Kalyoncu U**, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. *Arthritis Care Res (Hoboken)*. 2017;69:1606-1611.
10. Aydin SZ, Kilic L, Kucuksahin O, Ureyen SB, **Kalyoncu U**. Performances of inflammatory back pain criteria in axial psoriatic arthritis. *Rheumatology (Oxford)*. 2017 Aug 30. doi: 10.1093/rheumatology/kex307.

### **Erişkin Still Hastalığı**

1. **Kalyoncu U**, Buyukasik Y, Akdogan A, Karadag O, Bilgen SA, Kiraz S, Ertenli I, Calguneri M. Increased serum vitamin B12 levels are associated with adult-onset Still's disease with reactive macrophage activation syndrome. *Joint Bone Spine*. 2010;77:131-4.
2. **Kalyoncu U**, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, Balkarli A, Bes C, Ozmen M, Alibaz-Oner F, Erten S, Cagatay Y, Cetin GY, Yilmaz S, Yildiz F, Pamuk ON, Kucuksahin O, Kilic L, Yazisiz V, Karadag O, Koca SS, Hayran M, Akar S, Aksu K, Akkoc N, Keser G, Gonullu E, Kisacik B, Onat AM, Soy M, Inanc N, Direskeneli H, Sayarlioglu M, Erken E, Turgay M, Cefle A, Ertenli I, Pay S. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. *J Autoimmun*. 2016;69:59-63.
3. Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyükasik Y, Karadag O, Bilginer Y, Bilgen SA, Akdogan A, Kiraz S, Ertenli AI, Özen S, **Kalyoncu U**. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. *Scand J Rheumatol*. 2016 Jun 30:1-5.

### **Romatoid Artrit**

1. **Kalyoncu U**, Dougados M, Daurès JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis*. 2009;68:183-90.
2. **Kalyoncu U**, Karadag O, Akdogan A, Kisacik B, Erman M, Erguven S, Ertenli AI. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. *Scand J Infect Dis*. 2007;39(5):475-8.
3. Cobanoglu N, Ozcelik U, **Kalyoncu U**, Ozen S, Kiraz S, Gurcan N, Kaplan M, Dogru D, Yalcin E, Pekcan S, Kose M, Topaloglu R, Besbas N, Bakkaloglu A, Kiper N. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. *Int J Tuberc Lung Dis*. 2007;11:1177-82.
4. Yilmaz E, Uzun L, Rad AY, **Kalyoncu U**, Unal S, Denizli A. Specific adsorption of the autoantibodies from rheumatoid arthritis patient plasma using histidine-containing affinity beads. *J Biomater Sci Polym Ed*. 2008;19:875-92.
5. Serefhanoglu S, Tapan U, Ertenli I, **Kalyoncu U**, Uner A. Primary thyroid marginal zone B-cell lymphoma MALT-type in a patient with rheumatoid arthritis. *Med Oncol*. 2010;27:826-32.

6. Karadag O, **Kalyoncu U**, Akdogan A, Karadag YS, Bilgen SA, Ozbakir S, Filippucci E, Kiraz S, Ertenli I, Grassi W, Calguneri M. Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity. *Rheumatol Int.* 2012;32:2313-9.
7. Direskeneli H, Akkoç N, Bes C, Cakir N, Cefle A, Cobankara V, Dalkilic E, Dinc A, Ertenli I, Gul A, Hamuryudan V, Inanc M, **Kalyoncu U**, Karaaslan Y, Kasifoglu T, Keser G, Keskin G, Kisacik B, Kiraz S, Masatlioglu S, Onat AM, Ozbek S, Ozturk MA, Pamuk ON, Pay S, Pirildar T, Sayarlioglu M, Senel S, Senturk T, Tasan D, Terzioglu E, Yazici A, Yuçel E. Impact of rheumatoid arthritis in Turkey: a questionnaire study. *Clin Exp Rheumatol.* 2014;32:477-83.
8. Kilic L, Erden A, Bingham CO 3rd, Gossec L, **Kalyoncu U**. The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. *J Rheumatol.* 2016;43:1300-5.
9. Pamuk ÖN, Kalyoncu U, Aksu K, Omma A, Pehlivan Y, Çağatay Y, Küçükşahin O, Dönmez S, Çetin GY, Mercan R, Bayındır Ö, Çefle A, Yıldız F, Balkarlı A, Kılıç L, Çakır N, Kısacık B, Öksüz MF, Çobankara V, Onat AM, Sayarlioglu M, Öztürk MA, Pamuk GE, Akkoç N. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. *Rheumatol Int.* 2016;36:945-53.

### **Spondiloartritler**

1. Kisacik B, Tufan A, **Kalyoncu U**, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. *Joint Bone Spine.* 2008;75:291-4.
2. Aydin SZ, Karadag O, Filippucci E, Atagunduz P, Akdogan A, **Kalyoncu U**, Grassi W, Direskeneli H. Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study. *Rheumatology (Oxford).* 2010;49:578-82.
3. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U. Infliximab, a TNF- $\alpha$  antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. *Rheumatol Int.* 2012;32:323-30.
4. Karadağ O, Nakas D, **Kalyoncu U**, Akdoğan A, Kiraz S, Ertenli I. Effect of anti-TNF treatment on sleep problems in ankylosing spondylitis. *Rheumatol Int.* 2012;32:1909-13.
5. Sanal HT, Yılmaz S, Kalyoncu U, Cinar M, Simsek I, Erdem H, Pay S, Dinc A, Tayfun C. Value of DWI in visual assessment of activity of sacroiliitis in longstanding ankylosing spondylitis patients. *Skeletal Radiol.* 2013;42:289-93.
6. Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD. Sclerostin and Dkk-1 in patients with ankylosing spondylitis. *Acta Reumatol Port.* 2014;39:146-51.

7. Maraş Y, Akdoğan A, Kisacik B, Kiliç L, Yılmaz E, Tufan A, **Kalyoncu U**, Apraş Bilgen ŞŞ, Kiraz S, Ertenli Aİ, Çalgüneri M. MEFV mutation frequency and effecton disease severity in ankylosing spondylitis. Turk J Med Sci. 2014;44(2):203-7.

### **Ailesel Akdeniz Ateşi**

1. **Kalyoncu U**, Tufan A, Karadag O, Kisacik B, Akdogan A, Calguneri M. Rubinstein-Taybi syndrome and familial Mediterranean fever in a single patient: two distinct genetic diseases located on chromosome 16p13.3. J Natl Med Assoc. 2006;98:1692-3.
2. Akdogan A, Calguneri M, Yavuz B, Arslan EB, **Kalyoncu U**, Sahiner L, Karadag O, Ertenli I, Kiraz S, Aytemir K, Akata D, Tokgozoglu L, Oto A. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol. 2006;48:2351-3.
3. Dizdar O, **Kalyoncu U**, Karadag O, Akdogan A, Kiraz S, Ertenli I, Barista I, Calguneri M. Macrophage inflammatory protein-1alpha: a link between innate immunity and familial Mediterranean fever? Cytokine. 2007;37:92-5.
4. Kisacik B, **Kalyoncu U**, Erol MF, Karadag O, Yildiz M, Akdogan A, Kaptanoglu B, Hayran M, Ureten K, Ertenli I, Kiraz S, Calguneri M. Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin? Clin Rheumatol. 2007;26:2059-62.
5. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, **Kalyoncu U**, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol. 2007;34:1540-4.
6. **Kalyoncu U**, Eker A, Oguz KK, Kurne A, Kalan I, Topcuoglu AM, Anlar B, Bilginer Y, Arici M, Yılmaz E, Kiraz S, Calguneri M, Karabudak R. Familial Mediterranean fever and central nervous system involvement: a case series. Medicine (Baltimore). 2010;89:75-84.
7. Kisacik B, Erol MF, Yılmaz G, Yılmaz FM, Maras Y, **Kalyoncu U**, Karadag O, Kiraz S, Ertenli I, Calguneri M. Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis? Clin Rheumatol. 2012;31:225-9.
8. Bilgen SA, Kilic L, Akdogan A, Kiraz S, **Kalyoncu U**, Karadag O, Ertenli I, Dogan I, Calguneri M. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17:358-62.
9. Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, Kilic L, Oner SY, Yildiz F, Yılmaz S, Bakirli DE, Tufan MA, Yılmaz S, Yazisiz V, Pehlivan Y, Bes C, Cetin GY, Erten S, Gonullu E, Temel T, Sahin F, Akar S, Aksu K, Kalyoncu U, Direskeneli H, Erken E, Kisacik B, Sayarlioglu M, Korkmaz C. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford). 2014;53:741-5.

### **Behçet Hastalığı**

1. Yavuz B, Sahiner L, Akdogan A, Abali G, Aytemir K, Tokgozoglu L, **Kalyoncu U**, Karadag O, Kiraz S, Ertenli I, Calguneri M, Nazli N. Left and right ventricular function is impaired in Behçet's disease. Echocardiography. 2006;23:723-8.
2. Okutucu S, Karakulak UN, **Kalyoncu U**, Aytemir K. Cerebral and coronary artery aneurysms in a patient with Behçet's disease. Anadolu Kardiyol Derg. 2011;11:E32.
3. Emmungil H, Yaşar Bilge NŞ, Küçükşahin O, Kılıç L, Okutucu S, Gücenmez S, **Kalyoncu U**, Kaşifoğlu T, Turgay M, Aksu K. A rare but serious manifestation of Behçet's disease: intracardiac thrombus in 22 patients. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S87-92.
4. Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkarlı A, Kimyon G, Yazıcı A, Çnar M, Yılmaz S, Yıldız F, Bilge ŞY, Bilgin E, Coskun BN, Omma A, Çetin GY, Çağatay Y, Karaaslan Y, Sayarlioğlu M, Pehlivan Y, **Kalyoncu U**, Karadağ Ö, Kaşifoğlu T, Erken E, Pay S, Çefle A, Kisacık B, Onat AM, Çobankara V, Direskeneli H. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94:e494.

### **Bağ Dokusu Hastalıkları**

1. Karadag O, Calguneri M, Atalar E, Yavuz B, Akdogan A, **Kalyoncu U**, Bilgen SA, Ozer N, Ertenli AI, Ovunc K, Kiraz S. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol. 2007;26:695-9.
2. Karadag O, Calguneri M, Yavuz B, Atalar E, Akdogan A, **Kalyoncu U**, Kiraz S, Aksoyek S, Ozmen F, Ertenli AI. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Clin Rheumatol. 2007;26:1701-4.
3. Kepez A, Akdogan A, Sade LE, Deniz A, **Kalyoncu U**, Karadag O, Hayran M, Aytemir K, Ertenli I, Kiraz S, Calguneri M, Kabakci G, Tokgozoglu L. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. Echocardiography. 2008;25:191-7.
4. Kurne A, Isikay IC, Karlioguz K, Kalyoncu U, Aydın OF, Calguneri M, Karabudak R. A clinically isolated syndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation. J Neurol. 2008;255:1625-35.
5. Tozlu M, Kalyoncu U, Alp S, Unal S, Calguneri M. Diagnostic accuracy of Quantiferon TB test for patients with SLE and miliary tuberculosis. Rheumatol Int. 2009;29:1395-6.
6. Sinici I, **Kalyoncu U**, Karahan S, Kiraz S, Atalar E. Endothelial nitric oxide gene polymorphism and risk of systemic sclerosis: predisposition effect of T-786C promoter and protective effect of 27 bp repeats in Intron 4. Clin Exp Rheumatol. 2010;28:169-75.

7. Altınbaş A, Arik G, **Kalyoncu U**, Akdoğan A, Karadağ O, Kisacik B, Ertenli AI. Successful treatment of primary Sjögren's syndrome complicated with primary biliary cirrhosis and lung involvement. Turk J Gastroenterol. 2010;21:60-2.
8. Akdogan A, Kaya EB, Sahin A, Okutucu S, Yakut E, **Kalyoncu U**, Aksoy H, KaradagO, Calguneri M, Tokgozoglu L, Kiraz S, Ertenli I. Relationship between leftventricular diastolic dysfunction and six minute walk test in patients withsystemic sclerosis. Int J Rheum Dis. 2011;14:379-83.
9. Yildiz F, Tas DA, Açikalin A, Karakas T, Kalyoncu U, Erken E. Pigmented purpuric dermatosis associated with primary antiphospholipid syndrome. Intern Med. 2013;52:1255-7.
10. Bekircan-Kurt CE, Tuncer Kurne A, Erdem-Ozdamar S, Kalyoncu U, Karabudak R,Tan E. The course of myasthenia gravis with systemic lupus erythematosus. EurNeurol. 2014;72(5-6):326-9.

#### **Vaskülitler**

1. Karadag O, Aksu K, Sahin A, Zihni FY, Sener B, Inanc N, **Kalyoncu U**, Aydin SZ,Ascioglu S, Ocakci PT, Bilgen SA, Keser G, Inal V, Direskeneli H, Calguneri M,Ertenli I, Kiraz S. Assessment of latent tuberculosis infection in Takayasu arteritis with tuberculin skin test and Quantiferon-TB Gold test. Rheumatol Int. 2010;30:1483-7.
2. Batu ED, Karadag O, Taskiran EZ, **Kalyoncu U**, Aksentijevich I, Alikasifoglu M,Özen S. A Case Series of Adenosine Deaminase 2-deficient Patients EmphasizingTreatment and Genotype-phenotype Correlations. J Rheumatol. 2015;42:1532-4.
3. Er B, Koksall D, **Kalyoncu U**, Ozmen O, Emiralioglu N, Yalcin EG, Ergun E, Emri S. Takayasu's arteritis as the aetiology of unresolved fever in an adult patient with cystic fibrosis. Acta Clin Belg. 2015;70:295-8.
4. Kilic L, **Kalyoncu U**, Karadag O, Akdogan A, Dogan I, Bilgen SA, Kiraz S,Ertenli I. Inflammatory bowel diseases and Takayasu's arteritis: coincidence orassociation? Int J Rheum Dis. 2016 Feb 23. doi: 10.1111/1756-185X.12837.

#### **Diğerleri**

1. Arici M, Kahraman S, Gençtoy G, Altun B, **Kalyoncu U**, Oto A, Kirazli S, Erdem, Y, Yasavul U, Turgan C. Association of mineral metabolism with an increase incellular adhesion molecules: another link to cardiovascular risk in maintenancehaemodialysis? Nephrol Dial Transplant. 2006;21:999-1005.
2. Dizdar O, Barista I, **Kalyoncu U**, Karadag O, Hascelik G, Cila A, Pinar A, Celikli, Kars A, Tekuzman G. Biochemical markers of bone turnover in diagnosis ofmyeloma bone disease. Am J Hematol. 2007;82:185-91.
3. Dizdar O, Onal IK, Ozakin E, Karakiliç E, Karadag O, **Kalyoncu U**, Coşkun F,Buyukasik Y. Research for bleeding tendency in patients presenting withsignificant epistaxis. Blood Coagul Fibrinolysis. 2007;18:41-3.
4. Dizdar O, Karadağ O, **Kalyoncu U**, Kurt M, Ulger Z, Sardan YC, Unal S.Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital. J Eval Clin Pract. 2007;13:408-11.
5. **Kalyoncu U**, Dizdar O, ErkanDuman A, Karadag O, Tufan A, Yucel O, Tayfur O, Sen D, Ulger Z, Kepez A, Kocabas U, Haznedaroglu I. Alterations of von Willebrandfactor and ristocetin cofactor activity during atrial fibrillation. Clin Appl Thromb Hemost. 2009;15:103-8.

6. Kisacik B, Akdogan A, Maras Y, Kalyoncu U, Karadag O, Kilickap S, Calguneri M. Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy. *Rheumatol Int.* 2008;28:909-11.
7. **Kalyoncu U**, Yonem O, Calguneri M, Ersoy O, Karadag O, Akdogan A, Bilgen SA, Kiraz S, Ertenli I, Bayraktar Y. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. *Rheumatol Int.* 2009;29:777-80.
8. Akin S, Akin S, Karadag O, Kalyoncu U, Balci S, Ozgen B. Nasopharyngeal sarcoidosis: a rare involvement. *Rheumatol Int.* 2012;32:1407-9.
9. Konan A, **Kalyoncu U**, Dogan I, Kiliç YA, Karakoç D, Akdogan A, Kiraz S, Kaynaro Lu V, Onat D. Combined long-term steroid and immunosuppressive treatment regimen in granulomatous mastitis. *Breast Care (Basel).* 2012;7:297-301.
10. Yilmaz S, **Kalyoncu U**, Cinar M, Karadag O, Koca SS, Simsek I, Erdem H, Pay S, Dinc A. Features and publication rates of scientific abstracts presented at rheumatology congress--EULAR 2008. *Bull Hosp Jt Dis (2013).* 2013;71:124-7
11. Aksoy DY, Durusu Tanriover M, Unal S, Dizdar O, **Kalyoncu U**, Karakaya J, Unal S, Kale G. Burnout syndrome during residency in internal medicine and pediatrics in a country without working time directive. *Int J Health Care Qual Assur.* 2014;27:223-30.



## ***Prof. Umut Kalyoncu***

Prof. Umut Kalyoncu, who is now married with two children, was born in Bergama, Izmir in January 1976. Umut Kalyoncu finished his primary and secondary education in Bergama, studied first two years of high school at Trabzon Yomra Science High School and graduated from Bergama High School. In 1992, he started his university education at Hacettepe University School of Medicine in Turkish. With one year of preparatory school, he graduated after 7 years in 1999. In 2000, he started his assistantship at Hacettepe University, Department of Internal Medicine and worked as chief intern in between 2003-2004. He started his Rheumatology subspecialty in 2004 at Hacettepe University and worked as a specialist in between 2007-2010 at the Rheumatology Unit. In years 2010-2011 he completed his military service at Gülhane Military Medical Academy. In 2011, he was entitled to associate professorship. In between 2011-2012, he fulfilled his compulsory civil service at Antakya State Hospital. Since 2013 he has been working as an instructor at Hacettepe University School of Medicine, Department of Internal Medicine, Rheumatology Unit.

Prof. Umut Kalyoncu resided at The Hôpital Cochin, Paris, France as an observer on subjects of rheumatology and epidemiology in 2007 for 4 months. In between 2015-2016, at Clinical Rheumatology Unit of Johns Hopkins University, Maryland, USA, he worked as a fellow researcher and finished his postdoctoral studies. His basic research field is psoriatic arthritis. Since 2011, he has been a member of GRAPPA, an international psoriatic arthritis association. He has 82 original studies in refereed periodical publications. According to Web of Science database he has 224 scientific studies. Until December 2017, there has been 1046 remarks referring to these studies and his h-score is 15. He is a member of Turkish Internal Medicine Association and Turkish Rheumatology Association.

Prof. Umut Kalyoncu deals with the following rheumatic diseases; Spondiloarthritis (ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis), rheumatoid arthritis, connective tissue diseases (systemic lupus erythematosus, sjogren's syndrome, scleroderma, polymyositis, dermatomyositis), familial mediterranean fever (FMF), Behcet's disease, Sarcoidosis and Vascular diseases (vasculitis leucocitoclastica, henoch schönlein purpura, poliarteritis nodoza, takayasu arteritis, giant cell arteritis, wegener granulomatosis, churgh-strauss syndrome and microscopic polyangiitis).

## Academic studies of Prof. Umut Kalyoncu aligned with diseases

### Psoriatic Arthritis

11. **Kalyoncu U**, Gossec L, Nguyen M, Berdah L, Mazières B, Lequesne M, Dougados M. Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: results of a 10 years follow-up study of 507 patients (ECHODIAH study). *Joint Bone Spine*. 2009;76:389-93.
12. Gossec L, de Wit M, Kiltz U, Braun J, **Kalyoncu U**, Scivo R, MacCarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis*. 2014;73:1012-9.
13. Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, **Kalyoncu U**, Kiltz U, MacCarone M, Niedermayer D, Otsa K, Scivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. *Joint Bone Spine*. 2016;83:335-40.
14. **Kalyoncu U**, Ogdie A, Campbell W, Bingham CO 3rd, de Wit M, Gladman DD, Mease P, Steinkoenig I, Strand V, Riese VG, Orbai AM. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. *RMD Open*. 2016 Mar 3;2(1):e000217. doi:10.1136/rmdopen-2015-000217.
15. Gudu T, Etcheto A, de Wit M, Heiberg T, MacCarone M, Balanescu A, Balint PV, Niedermayer DS, Cañete JD, Helliwell P, **Kalyoncu U**, Kiltz U, Otsa K, Veale DJ, de Vlam K, Scivo R, Stamm T, Kvien TK, Gossec L. Fatigue in psoriatic arthritis – across-sectional study of 246 patients from 13 countries. *Joint Bone Spine*. 2016;83:439-43.
16. Orbai AM, Mease PJ, de Wit M, **Kalyoncu U**, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A. Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. *J Rheumatol*. 2016;43:965-9.
17. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, **Kalyoncu U**, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis*. 2017;76:673-680.
18. **Kalyoncu U**, Bayindir Ö, Ferhat Öksüz M, Doğru A, Kimyon G, Tarhan EF, Erden A, Yavuz Ş, Can M, Çetin GY, Kılıç L, Küçükşahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yilmazer B, Atakan N, Aydın SZ; Psoriatic Arthritis Registry of Turkey Study Group. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. *Rheumatology (Oxford)*. 2017;56:279-286.

19. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, **Kalyoncu U**, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scriver R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. *Arthritis Care Res (Hoboken)*. 2017;69:1606-1611.
20. Aydin SZ, Kilic L, Kucuksahin O, Ureyen SB, **Kalyoncu U**. Performances of inflammatory back pain criteria in axial psoriatic arthritis. *Rheumatology (Oxford)*. 2017 Aug 30. doi: 10.1093/rheumatology/kex307.

#### **Adult Still's disease**

4. **Kalyoncu U**, Buyukasik Y, Akdogan A, Karadag O, Bilgen SA, Kiraz S, Ertenli I, Calguneri M. Increased serum vitamin B12 levels are associated with adult-onset Still's disease with reactive macrophage activation syndrome. *Joint Bone Spine*. 2010;77:131-4.
5. **Kalyoncu U**, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, Balkarli A, Bes C, Ozmen M, Alibaz-Oner F, Erten S, Cagatay Y, Cetin GY, Yilmaz S, Yildiz F, Pamuk ON, Kucuksahin O, Kilic L, Yazisiz V, Karadag O, Koca SS, Hayran M, Akar S, Aksu K, Akkoc N, Keser G, Gonullu E, Kisacik B, Onat AM, Soy M, Inanc N, Direskeneli H, Sayarlioglu M, Erken E, Turgay M, Cefle A, Ertenli I, Pay S. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. *J Autoimmun*. 2016;69:59-63.
6. Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyüksak Y, Karadag O, Bilginer Y, Bilgen SA, Akdogan A, Kiraz S, Ertenli AI, Özen S, **Kalyoncu U**. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. *Scand J Rheumatol*. 2016 Jun 30:1-5.

#### **Rheumatoid Arthritis**

10. **Kalyoncu U**, Dougados M, Daurès JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis*. 2009;68:183-90.
11. **Kalyoncu U**, Karadag O, Akdogan A, Kisacik B, Erman M, Erguven S, Ertenli AI. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. *Scand J Infect Dis*. 2007;39(5):475-8.
12. Cobanoglu N, Ozcelik U, **Kalyoncu U**, Ozen S, Kiraz S, Gurcan N, Kaplan M, Dogru D, Yalcin E, Pekcan S, Kose M, Topaloglu R, Besbas N, Bakkaloglu A, Kiper N. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. *Int J Tuberc Lung Dis*. 2007;11:1177-82.
13. Yilmaz E, Uzun L, Rad AY, **Kalyoncu U**, Unal S, Denizli A. Specific adsorption of the autoantibodies from rheumatoid arthritis patient plasma using histidine-containing affinity beads. *J Biomater Sci Polym Ed*. 2008;19:875-92.
14. Serefhanoglu S, Tapan U, Ertenli I, **Kalyoncu U**, Uner A. Primary thyroid marginal zone B-cell lymphoma MALT-type in a patient with rheumatoid arthritis. *Med Oncol*. 2010;27:826-32.

15. Karadag O, **Kalyoncu U**, Akdogan A, Karadag YS, Bilgen SA, Ozbakir S, Filippucci E, Kiraz S, Ertenli I, Grassi W, Calgüneri M. Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity. *Rheumatol Int.* 2012;32:2313-9.
16. Direskeneli H, Akkoç N, Bes C, Cakir N, Cefle A, Cobankara V, Dalkilic E, Dinc A, Ertenli I, Gul A, Hamuryudan V, Inanc M, **Kalyoncu U**, Karaaslan Y, Kasifoglu T, Keser G, Keskin G, Kisacik B, Kiraz S, Masatlioglu S, Onat AM, Ozbek S, Ozturk MA, Pamuk ON, Pay S, Pirildar T, Sayarlioglu M, Senel S, Senturk T, Tasan D, Terzioglu E, Yazici A, Yuçel E. Impact of rheumatoid arthritis in Turkey: a questionnaire study. *Clin Exp Rheumatol.* 2014;32:477-83.
17. Kilic L, Erden A, Bingham CO 3rd, Gossec L, **Kalyoncu U**. The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. *J Rheumatol.* 2016;43:1300-5.
18. Pamuk ÖN, Kalyoncu U, Aksu K, Omma A, Pehlivan Y, Çağatay Y, Küçükşahin O, Dönmez S, Çetin GY, Mercan R, Bayındır Ö, Çefle A, Yıldız F, Balkarlı A, Kılıç L, Çakır N, Kısacık B, Öksüz MF, Çobankara V, Onat AM, Sayarlioglu M, Öztürk MA, Pamuk GE, Akkoç N. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. *Rheumatol Int.* 2016;36:945-53.

#### **Spondiloarthritis**

8. Kisacik B, Tufan A, **Kalyoncu U**, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. *Joint Bone Spine.* 2008;75:291-4.
9. Aydin SZ, Karadag O, Filippucci E, Atagunduz P, Akdogan A, **Kalyoncu U**, Grassi W, Direskeneli H. Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study. *Rheumatology (Oxford).* 2010;49:578-82.
10. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, Calguneri M, Kalyoncu U. Infliximab, a TNF- $\alpha$  antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. *Rheumatol Int.* 2012;32:323-30.
11. Karadağ O, Nakas D, **Kalyoncu U**, Akdoğan A, Kiraz S, Ertenli I. Effect of anti-TNF treatment on sleep problems in ankylosing spondylitis. *Rheumatol Int.* 2012;32:1909-13.
12. Sanal HT, Yilmaz S, Kalyoncu U, Cinar M, Simsek I, Erdem H, Pay S, Dinc A, Tayfun C. Value of DWI in visual assessment of activity of sacroiliitis in longstanding ankylosing spondylitis patients. *Skeletal Radiol.* 2013;42:289-93.
13. Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD. Sclerostin and Dkk-1 in patients with ankylosing spondylitis. *Acta Reumatol Port.* 2014;39:146-51.
14. Maraş Y, Akdoğan A, Kisacik B, Kiliç L, Yilmaz E, Tufan A, **Kalyoncu U**, Apraş Bilgen ŞŞ, Kiraz S, Ertenli Aİ, Çalgüneri M. MEFV mutation frequency and effect on disease severity in ankylosing spondylitis. *Turk J Med Sci.* 2014;44(2):203-7.

### **Familial Mediterranean Fever**

10. **Kalyoncu U**, Tufan A, Karadag O, Kisacik B, Akdogan A, Calguneri M. Rubinstein-Taybi syndrome and familial Mediterranean fever in a single patient: two distinct genetic diseases located on chromosome 16p13.3. *J Natl Med Assoc.* 2006;98:1692-3.
11. Akdogan A, Calguneri M, Yavuz B, Arslan EB, **Kalyoncu U**, Sahiner L, Karadag O, Ertenli I, Kiraz S, Aytemir K, Akata D, Tokgozoglu L, Oto A. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. *J Am Coll Cardiol.* 2006;48:2351-3.
12. Dizdar O, **Kalyoncu U**, Karadag O, Akdogan A, Kiraz S, Ertenli I, Barista I, Calguneri M. Macrophage inflammatory protein-1alpha: a link between innate immunity and familial Mediterranean fever? *Cytokine.* 2007;37:92-5.
13. Kisacik B, **Kalyoncu U**, Erol MF, Karadag O, Yildiz M, Akdogan A, Kaptanoglu B, Hayran M, Ureten K, Ertenli I, Kiraz S, Calguneri M. Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin? *Clin Rheumatol.* 2007;26:2059-62.
14. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, **Kalyoncu U**, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. *J Rheumatol.* 2007;34:1540-4.
15. **Kalyoncu U**, Eker A, Oguz KK, Kurne A, Kalan I, Topcuoglu AM, Anlar B, Bilginer Y, Arici M, Yilmaz E, Kiraz S, Calguneri M, Karabudak R. Familial Mediterranean fever and central nervous system involvement: a case series. *Medicine (Baltimore).* 2010;89:75-84.
16. Kisacik B, Erol MF, Yilmaz G, Yilmaz FM, Maras Y, **Kalyoncu U**, Karadag O, Kiraz S, Ertenli I, Calguneri M. Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis? *Clin Rheumatol.* 2012;31:225-9.
17. Bilgen SA, Kilic L, Akdogan A, Kiraz S, **Kalyoncu U**, Karadag O, Ertenli I, Dogan I, Calguneri M. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. *J Clin Rheumatol.* 2011;17:358-62.
18. Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, Kilic L, Oner SY, Yildiz F, Yilmaz S, Bakirli DE, Tufan MA, Yilmaz S, Yazisiz V, Pehlivan Y, Bes C, Cetin GY, Erten S, Gonullu E, Temel T, Sahin F, Akar S, Aksu K, Kalyoncu U, Direskeneli H, Erken E, Kisacik B, Sayarlioglu M, Korkmaz C. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. *Rheumatology (Oxford).* 2014;53:741-5.

### **Behçet's Disease**

5. Yavuz B, Sahiner L, Akdogan A, Abali G, Aytemir K, Tokgozoglu L, **Kalyoncu U**, Karadag O, Kiraz S, Ertenli I, Calguneri M, Nazli N. Left and right ventricular function is impaired in Behçet's disease. *Echocardiography.* 2006;23:723-8.

6. Okutucu S, Karakulak UN, **Kalyoncu U**, Aytemir K. Cerebral and coronary artery aneurysms in a patient with Behçet's disease. *Anadolu Kardiyol Derg.* 2011;11:E32.
7. Emmungil H, Yaşar Bilge NŞ, Küçükşahin O, Kılıç L, Okutucu S, Gücenmez S, **Kalyoncu U**, Kaşifoğlu T, Turgay M, Aksu K. A rare but serious manifestation of Behçet's disease: intracardiac thrombus in 22 patients. *Clin Exp Rheumatol.* 2014;32(4 Suppl 84):S87-92.
8. Alibaz-Oner F, Karadeniz A, Yılmaz S, Balkar A, Kimyon G, Yazc A, Çnar M, Yılmaz S, Yldz F, Bilge ŞY, Bilgin E, Coskun BN, Omma A, Çetin GY, Çağatay Y, Karaaslan Y, Sayarlioğlu M, Pehlivan Y, **Kalyoncu U**, Karadağ Ö, Kaşifoğlu T, Erken E, Pay S, Çefle A, Kisacik B, Onat AM, Çobankara V, Direskeneli H. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. *Medicine (Baltimore).* 2015;94:e494.

### **Connective Tissue Diseases**

11. Karadağ O, Calguneri M, Atalar E, Yavuz B, Akdogan A, **Kalyoncu U**, Bilgen SA, Ozer N, Ertenli AI, Ovunc K, Kiraz S. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. *Clin Rheumatol.* 2007;26:695-9.
12. Karadağ O, Calguneri M, Yavuz B, Atalar E, Akdogan A, **Kalyoncu U**, Kiraz S, Aksoyek S, Ozmen F, Ertenli AI. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? *Clin Rheumatol.* 2007;26:1701-4.
13. Kepez A, Akdogan A, Sade LE, Deniz A, **Kalyoncu U**, Karadağ O, Hayran M, Aytemir K, Ertenli I, Kiraz S, Calguneri M, Kabakci G, Tokgozoglu L. Detection of subclinical cardiac involvement in systemic sclerosis by echocardiographic strain imaging. *Echocardiography.* 2008;25:191-7.
14. Kurne A, Isikay IC, Karlioguz K, Kalyoncu U, Aydin OF, Calguneri M, Karabudak R. A clinically isolated syndrome: a challenging entity: multiple sclerosis or collagen tissue disorders: clues for differentiation. *J Neurol.* 2008;255:1625-35.
15. Tozlu M, Kalyoncu U, Alp S, Unal S, Calguneri M. Diagnostic accuracy of Quantiferon TB test for patients with SLE and military tuberculosis. *Rheumatol Int.* 2009;29:1395-6.
16. Sinici I, **Kalyoncu U**, Karahan S, Kiraz S, Atalar E. Endothelial nitric oxide gene polymorphism and risk of systemic sclerosis: predisposition effect of T-786C promoter and protective effect of 27 bp repeats in Intron 4. *Clin Exp Rheumatol.* 2010;28:169-75.
17. Altınbaş A, Arik G, **Kalyoncu U**, Akdoğan A, Karadağ O, Kisacik B, Ertenli AI. Successful treatment of primary Sjögren's syndrome complicated with primary biliary cirrhosis and lung involvement. *Turk J Gastroenterol.* 2010;21:60-2.
18. Akdogan A, Kaya EB, Sahin A, Okutucu S, Yakut E, **Kalyoncu U**, Aksoy H, Karadağ O, Calguneri M, Tokgozoglu L, Kiraz S, Ertenli I. Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis. *Int J Rheum Dis.* 2011;14:379-83.
19. Yildiz F, Tas DA, Açikalın A, Karakas T, Kalyoncu U, Erken E. Pigmented purpuric dermatosis associated with primary antiphospholipid syndrome. *Intern Med.* 2013;52:1255-7.

20. Bekircan-Kurt CE, Tuncer Kurne A, Erdem-Ozdamar S, Kalyoncu U, Karabudak R, Tan E. The course of myasthenia gravis with systemic lupus erythematosus. *EurNeurol*. 2014;72(5-6):326-9.

### Vascular Diseases

5. Karadag O, Aksu K, Sahin A, Zihni FY, Sener B, Inanc N, **Kalyoncu U**, Aydin SZ, Ascioğlu S, Ocakci PT, Bilgen SA, Keser G, Inal V, Direskeneli H, Calguneri M, Ertenli I, Kiraz S. Assessment of latent tuberculosis infection in Takayasu arteritis with tuberculin skin test and Quantiferon-TB Gold test. *Rheumatol Int*. 2010;30:1483-7.
6. Batu ED, Karadag O, Taskiran EZ, **Kalyoncu U**, Aksentijevich I, Alikasifoglu M, Özen S. A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. *J Rheumatol*. 2015;42:1532-4.
7. Er B, Koksall D, **Kalyoncu U**, Ozmen O, Emiralioglu N, Yalcin EG, Ergun E, Emri S. Takayasu's arteritis as the aetiology of unresolved fever in an adult patient with cystic fibrosis. *Acta Clin Belg*. 2015;70:295-8.
8. Kilic L, **Kalyoncu U**, Karadag O, Akdogan A, Dogan I, Bilgen SA, Kiraz S, Ertenli I. Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association? *Int J Rheum Dis*. 2016 Feb 23. doi: 10.1111/1756-185X.12837.

### Others

12. Arici M, Kahraman S, Gençtoý G, Altun B, **Kalyoncu U**, Oto A, Kirazli S, Erdem, Y, Yasavul U, Turgan C. Association of mineral metabolism with an increase in cellular adhesion molecules: another link to cardiovascular risk in maintenance haemodialysis? *Nephrol Dial Transplant*. 2006;21:999-1005.
13. Dizdar O, Barista I, **Kalyoncu U**, Karadag O, Hascelik G, Cila A, Pinar A, Celikli, Kars A, Tekuzman G. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. *Am J Hematol*. 2007;82:185-91.
14. Dizdar O, Onal IK, Ozakin E, Karakiliç E, Karadag O, **Kalyoncu U**, Coşkun F, Buyukasik Y. Research for bleeding tendency in patients presenting with significant epistaxis. *Blood Coagul Fibrinolysis*. 2007;18:41-3.
15. Dizdar O, Karadağ O, **Kalyoncu U**, Kurt M, Ulger Z, Sardan YC, Unal S. Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital. *J Eval Clin Pract*. 2007;13:408-11.
16. **Kalyoncu U**, Dizdar O, Erkan Duman A, Karadag O, Tufan A, Yucel O, Tayfur O, Sen D, Ulger Z, Kepez A, Kocabas U, Haznedaroglu I. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation. *Clin Appl Thromb Hemost*. 2009;15:103-8.
17. Kisacik B, Akdogan A, Maras Y, Kalyoncu U, Karadag O, Kilickap S, Calguneri M. Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy. *Rheumatol Int*. 2008;28:909-11.
18. **Kalyoncu U**, Yonem O, Calguneri M, Ersoy O, Karadag O, Akdogan A, Bilgen SA, Kiraz S, Ertenli I, Bayraktar Y. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. *Rheumatol Int*. 2009;29:777-80.
19. Akin S, Akin S, Karadag O, Kalyoncu U, Balci S, Ozgen B. Nasopharyngeal sarcoidosis: a rare involvement. *Rheumatol Int*. 2012;32:1407-9.

20. Konan A, Kalyoncu U, Dogan I, Kiliç YA, Karakoç D, Akdogan A, Kiraz S, Kaynaro Lu V, Onat D. Combined long-term steroid and immunosuppressive treatment regimen in granulomatous mastitis. *Breast Care (Basel)*. 2012;7:297-301.
21. Yilmaz S, Kalyoncu U, Cinar M, Karadag O, Koca SS, Simsek I, Erdem H, Pay S, Dinc A. Features and publication rates of scientific abstracts presented at rheumatology congress--EULAR 2008. *Bull Hosp Jt Dis* (2013). 2013;71:124-7
22. Aksoy DY, Durusu Tanriover M, Unal S, Dizdar O, Kalyoncu U, Karakaya J, Unal S, Kale G. Burnout syndrome during residency in internal medicine and pediatrics in a country without working time directive. *Int J Health Care Qual Assur*. 2014;27:223-30.